Friday, July 10, 2026

pharma · Advanced Solid Tumor · Chronic Lymphocytic Leukemia

BEONE MEDICINES AUS

BEONE MEDICINES AUS is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Advanced Solid Tumor, Chronic Lymphocytic Leukemia, Solid Tumor, Adult, Mantle Cell Lymphoma, Previous

Cambridge, USA HQ
2010 Founded
3,177 Employees
TGA registrant Type
Company details
Clinical program

PD-1/PD-L1 inhibitors

Phase 2 · small molecule · Borderline Resectable Carcinoma

PD-1/PD-L1 inhibitors for Borderline Resectable Carcinoma is a Phase 2 program (small_molecule) at BEONE MEDICINES AUS PTY LTD with 1 ClinicalTrials.gov record(s).

Internal code SUMC-ILDR03

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
BEONE MEDICINES AUS PTY LTD
Phase
Phase 2
Modality
small_molecule
Indication
Borderline Resectable Carcinoma
Status
active
Trials
1